Published on: 15 July 2013
Skip to main content
In a Commentary published in JITC, members of the SITC Executive Committee and JITC Section Editor Dr. Leisha A. Emens examine the need for finding an appropriate balance between the rapid development of promising cancer immunotherapeutics through clinical trials and ensuring patient safety through appropriate and scalable trial design.
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
Michael Ong, et al
Urothelial carcinoma of donor origin in a kidney transplant patient
Rosa M. Michel Ortega, et al
Acute visual loss after ipilimumab treatment for metastatic melanoma
Melissa A. Wilson, et al
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015
Paolo A. Ascierto, et al
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
Lauren Van Der Kraak, et al
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Bridgette A. Kanz, et al
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy...
Genevieve M. Weir, et al
Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
MacLean Hall, et al
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton and Mary L. Disis
High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma...
S. Chow, et al
View and search for all articles in the journal here.
Published on: 15 July 2013
Published on: 29 July 2013
Published on: 27 August 2013
Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
JITC welcomes submissions to the following sections:
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.
Read all of the articles here.
As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts published in JITC.
Two $1,000 USD awards will be given for the JITC Best Clinical/Translational Paper and the JITC Best Basic Science Paper published in JITC.
The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member-driven society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The Society has become the forum for innovative discussions in the field.
Society members include nearly 1000 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.
It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.